FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  CROCKER GARY L						2. Issuer Name and Ticker or Trading Symbol  MERRIMACK PHARMACEUTICALS										Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
		INC [ MACK ]										Office		0							
(Last) (First) (Middle) C/O MERRIMACK PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 08/10/2023										X Officer (give title Other (specify below)  See Remarks					
ONE BROADWAY 14TH FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)																X Form filed by One Reporting Person					
CAMBRIDGE MA 02142															Form filed by More than One Reporting Person						
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication															
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
		Table	1-	Non-Deriva	tive	Secu	ritie	s A	cqu	ired,	Dis	posed o	of, or	Bene	ficial	y Own	ed				
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yea			ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and				nd 5)	Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								-	Code	v			(A) or (D)	Price			ted action(s) 3 and 4)				
Common Stock				08/10/2023	3				P		2	2,000	A	A \$12.5196		133,105		I		See footnote <sup>(2)</sup>	
Common Stock 08/11/2				08/11/2023	3				P		2	2,000	A	\$12.4	326 <sup>(3)</sup>	133,105				See footnote <sup>(2)</sup>	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any					ransaction Code (Instr. )		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)				7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Price of erivative ecurity 1str. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ully	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code	e V	(A)	(A) (D)		Date ) Exercisa		Expiration Date	n Titl	or Num of e Shar							

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.48 to \$12.54, inclusive on August 10, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- $2. \ Shares \ held \ by \ Crocker \ Family \ Investments, \ LLC, \ over \ which \ Reporting \ Person \ is \ the \ Managing \ Member.$
- 3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$12.38 to \$12.50, inclusive on August 11, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

## Remarks:

Chairman, President, and Treasurer

/s/ Gary L. Crocker

08/14/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.